查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1808940

額顳葉失智症市場，按藥物類別、按疾病適應症、按配銷通路、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Frontotemporal Dementia Market, By Drug Class, By Disease Indication, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 304 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年額顳葉失智症市場規模價值 2.4518 億美元，2025 年至 2032 年的複合年成長率為 7.20%。

額顳葉疾病是一種導致大腦額葉或顳葉神經細胞退化的神經系統疾病。這類疾病包括失智症、進行性核上性麻痺和原發性進行性失語症，會對行為、語言、運動和個性產生重大影響，限制人們執行日常任務的能力。額顳葉疾病，也稱為額顳葉變性，是一種主要影響額葉和顳葉的神經系統疾病。這種疾病的特徵是神經細胞進行性喪失和失智症的發生。

額顳葉失智症市場-市場動態

神經退化性疾病盛行率上升推動市場成長

神經退化性疾病的盛行率日益上升，尤其是在老化和高遺傳風險族群中，是額顳葉失智症 (FTD) 市場的主要驅動力。 FTD 是早發性失智症最常見的原因之一，隨著認知度、診斷和報告水平的提高，全球發現了越來越多的病例。隨著預期壽命的延長和神經系統篩檢的普及，對有效 FTD 治療的需求也隨之成長。這一趨勢正鼓勵製藥和生技公司投資新型療法，例如基因療法和抗 tau 蛋白藥物。此外，醫療保健系統將早期發現和介入放在首位，這推動了市場的成長。全球神經退化性疾病的負擔使得 FTD 仍然是尚未滿足醫療需求的關鍵領域。

額顳葉失智症市場－關鍵洞察

根據我們的研究分析師的分析，預測期內（2025-2032 年）全球市場預計年複合成長率約為 7.20%

根據藥物類別的細分，預計抗憂鬱藥物將在 2025 年佔據最大的市場佔有率。

根據疾病適應症細分，額顳葉失智症是2025年最常見的疾病適應症。

2025年，北美將成為收入最高的地區。

額顳葉失智症市場-細分分析：

全球額顳葉失智症市場根據藥物類別、疾病適應症、配銷通路和地區進行細分。

根據藥物類別，市場分為五類：認知增強劑、抗憂鬱藥、抗精神病藥、中樞神經興奮劑和其他藥物類別。預計抗憂鬱藥物將在預測期內帶來豐厚的市場機會。抗憂鬱藥物主要用於治療憂鬱症和其他疾病，例如心境惡劣障礙、強迫症 (OCD)、焦慮症、神經性疼痛、飲食失調和慢性疼痛。醫生經常開立各種類型的抗憂鬱藥物來改善患者的健康狀況。選擇性血清素再攝取抑制劑 (SSRI) 已被證明對治療額顳葉疾病有益。

根據疾病適應症，市場分為三類：額顳葉失智症、運動障礙、原發性進行性失語症。額顳葉失智症在2025年佔據額顳葉失智症市場的最大佔有率，預計在2026-2030年的預測期內將進一步成長。額顳葉失智症是一組罕見的腦部疾病，主要影響額葉和顳葉，導致人格、語言和行為的改變。儘管額顳葉失智症經常被誤診為阿茲海默症，但其發病年齡通常較年輕，介於40至65歲之間。

額顳葉失智症市場—地理洞察

北美憑藉其先進的醫療基礎設施、高昂的醫療支出以及廣泛的研發活動，佔據市場主導地位。尤其是美國，由於其龐大的老年人口和大型製藥公司的存在，在區域市場中佔據主導地位。該地區重視早期診斷和干涉，並開展了廣泛的宣傳活動，鞏固了其市場領導地位。預計北美市場在預測期內將維持穩定的複合年成長率。

預計亞太地區將在預測期內經歷最快速的成長。該地區龐大的老齡人口，尤其是在中國、日本和印度，推動了對失智症治療的需求。醫療保健投資的增加和先進技術的採用有助於推動市場成長。該地區各國政府正在積極推動宣傳活動，並資助研究項目，以應對日益加重的失智症負擔。預計亞太市場將以快速的複合年成長率成長，這反映了該地區對改善醫療保健基礎設施和增加失智症治療可及性的重視。

額顳葉失智症市場-競爭格局：

額顳葉失智症 (FTD) 市場瞬息萬變，製藥巨頭和創新生物技術公司競相開發針對這種複雜神經退化性疾病的有效療法。包括 Transposon Therapeutics、阿斯特捷利康公司、Alector Inc.、輝瑞公司和 Denali Therapeutics Inc. 在內的領先公司正在進行針對 tau 蛋白積聚和前顆粒蛋白缺乏症的疾病修飾療法的高級研究。孤兒藥資格認定、產學合作的不斷加強以及精準診斷領域投資的不斷增加，都在推動市場向前發展。

最新動態：

2024年7月，美國食品藥物管理局（FDA）批准Alpha Cognition的口服療法ZUNVEYL在美國用於治療阿茲海默症。這種新型藥物具有獨特的雙重作用機制，可改善認知功能，同時比現有療法具有更好的耐受性。 ZUNVEYL是阿茲海默症護理領域的一項有希望的進展，旨在滿足患者和照護者尚未滿足的需求。

目錄

第1章：額顳葉失智症市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 額顳葉失智症市場片段（依藥物類別）
    • 額顳葉失智症市場片段（依疾病適應症）
    • 額顳葉失智症市場片段（依配銷通路）
    • 額顳葉失智症市場（依國家）
    • 額顳葉失智症市場片段（按地區）
  • 競爭洞察

第3章：額顳葉失智症主要市場趨勢

  • 額顳葉失智症市場促進因素
    • 市場促進因素的影響分析
  • 額顳葉失智症市場限制
    • 市場限制的影響分析
  • 額顳葉失智症市場機會
  • 額顳葉失智症市場未來趨勢

第4章：額顳葉失智症產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：額顳葉失智症市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：額顳葉失智症市場格局

  • 2024年額顳葉失智症市場佔有率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：額顳葉失智症市場－依藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 認知增強劑
    • 抗憂鬱藥
    • 抗精神病藥物
    • 中樞神經興奮劑
    • 其他藥物類別

第 8 章：額顳葉失智症市場 - 按疾病適應症

  • 概述
    • 按疾病適應症分類的細分佔有率分析
    • 額顳葉失智症
    • 運動障礙
    • 原發性進行性失語症

第9章：額顳葉失智症市場－按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 網路藥局
    • 零售藥局

第10章：額顳葉失智症市場－依地區分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美額顳葉失智症主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（依藥品類別）
    • 北美市場規模及預測（依疾病類型分類）
    • 北美市場規模及預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲額顳葉失智症主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（依藥品類別）
    • 歐洲市場規模及預測（依疾病類型分類）
    • 歐洲市場規模及預測（按配銷通路）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區額顳葉失智症主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依藥品類別）
    • 亞太地區市場規模及預測（依疾病類型分類）
    • 亞太地區市場規模及預測（按配銷通路）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲額顳葉失智症主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依藥品類別）
    • 拉丁美洲市場規模及預測（依疾病類型分類）
    • 拉丁美洲市場規模及預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲額顳葉失智症主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依藥物類別）
    • MEA 市場規模及預測（依疾病類型分類）
    • MEA 市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 11 章：額顳葉失智症產業主要供應商分析

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • Transposon Therapeutics
    • AstraZeneca plc
    • Alector Inc.
    • Pfizer Inc.
    • Denali Therapeutics Inc.
    • Johnson & Johnson Services Inc.
    • Prevail Therapeutics
    • Wave Life Sciences
    • GlaxoSmithKline plc
    • TauRx Pharmaceuticals Ltd.
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5569

Frontotemporal Dementia Market size was valued at US$ 245.18 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

Frontotemporal diseases are neurological conditions that cause nerve cell degeneration in the brain's frontal or temporal lobes. This condition, which includes dementia, progressive supranuclear palsy, and primary progressive aphasia, has a significant impact on behavior, language, movement, and personality, limiting people's ability to carry out daily tasks. Frontotemporal disorders, also known as frontotemporal lobar degeneration, are neurological conditions that primarily affect the frontal and temporal lobes. This condition is defined by the progressive loss of nerve cells and the onset of dementia.

Frontotemporal Dementia Market- Market Dynamics

Rising Prevalence of Neurodegenerative Disorders Drives Market Growth

The growing prevalence of neurodegenerative disorders, particularly in the aging and genetically at-risk populations, is a major driver of the frontotemporal dementia (FTD) market. FTD is one of the most common causes of early-onset dementia, and more cases are being discovered around the world as awareness, diagnostics, and reporting improve. As life expectancy rises and neurological screening becomes more widely available, the demand for effective FTD treatments has increased. This trend is encouraging pharmaceutical and biotech companies to invest in new therapeutics, such as gene therapies and anti-tau drugs. In addition, healthcare systems are prioritizing early detection and intervention, which is driving market growth. The global burden of neurodegenerative diseases ensures that FTD remains a critical area of unmet medical need.

Frontotemporal Dementia Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)

According to the segmentation of drug classes, antidepressants were expected to hold the largest market share in 2025.

According to segmentation of disease indications, frontotemporal dementia was the most common disease indication in 2025.

In 2025, North America ranked as the top revenue-generating region.

Frontotemporal Dementia Market- Segmentation Analysis:

The Global Frontotemporal Dementia Market is segmented on the basis of Drug Class, Disease Indication, Distribution Channel, and Region.

The market is separated into five groups according to the drug class: Cognitive Enhancers, Antidepressants, Antipsychotics, CNS Stimulants and Other Drug Classes. Antidepressants are expected to provide a lucrative opportunity during the forecast period. Antidepressant medications are primarily used to treat depressive disorders and other conditions such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain. Physicians frequently prescribe various types of antidepressants to improve patient health. Selective serotonin reuptake inhibitors (SSRIs) have proven beneficial in treating frontotemporal disorders.

The market is divided into three categories based on Disease Indication: Frontotemporal Dementia, Movement Disorders, and Primary Progressive Aphasia. Frontotemporal Dementia hold the largest market share in the Frontotemporal Dementia Market in 2025, and it is expected to grow further during the forecast period 2026-2030. Frontotemporal dementia is a collection of rare brain disorders that primarily affect the frontal and temporal lobes, resulting in changes in personality, language, and behavior. Despite frequently being misdiagnosed as Alzheimer's disease, frontotemporal dementia usually appears at a younger age, between 40 and 65.

Frontotemporal Dementia Market- Geographical Insights

North America dominates the market, owing to its advanced healthcare infrastructure, high healthcare expenditure, and extensive R&D activities. The United States, in particular, dominates the regional market due to its large elderly population and the presence of major pharmaceutical companies. The region's emphasis on early diagnosis and intervention, combined with extensive awareness campaigns, adds to its market leadership. The North American market is expected to grow at a steady CAGR over the forecast period.

The Asia Pacific region is expected to experience the most rapid growth during the forecast period. The region's large aging population, particularly in China, Japan, and India, drives up demand for dementia treatments. Increased healthcare investment and the adoption of advanced technologies help to drive market growth. The region's governments are actively promoting awareness campaigns and funding research initiatives to address the growing burden of dementia. The Asia Pacific market is expected to grow at a rapid CAGR, reflecting the region's emphasis on improving healthcare infrastructure and increasing access to dementia treatment.

Frontotemporal Dementia Market- Competitive Landscape:

The frontotemporal dementia (FTD) market is rapidly changing, with pharmaceutical giants and innovative biotech firms competing to develop effective treatments for this complex neurodegenerative condition. Leading companies, including Transposon Therapeutics, AstraZeneca plc, Alector Inc., Pfizer Inc., and Denali Therapeutics Inc., are conducting advanced research on disease-modifying treatments for tau protein accumulation and progranulin deficiencies. Orphan drug designations, growing collaborations between industry and academia, and increased investment in precision diagnostics are all driving the market forward.

Recent Developments:

In July 2024, The FDA has approved Alpha Cognition's oral therapy, ZUNVEYL, for the treatment of Alzheimer's disease in the US. This novel medication has a unique dual mechanism of action that improves cognitive function while providing better tolerability than existing treatments. ZUNVEYL is a promising advancement in Alzheimer's care that seeks to meet the unmet needs of patients and caregivers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Transposon Therapeutics
  • AstraZeneca plc
  • Alector Inc.
  • Pfizer Inc.
  • Denali Therapeutics Inc.
  • Johnson & Johnson Services Inc.
  • Prevail Therapeutics
  • Wave Life Sciences
  • GlaxoSmithKline plc
  • TauRx Pharmaceuticals Ltd.
  • Others

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Cognitive Enhancers
  • Antidepressants
  • Antipsychotics
  • CNS Stimulants
  • Other Drug Classes

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Frontotemporal Dementia
  • Movement Disorders
  • Primary Progressive Aphasia

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Frontotemporal Dementia Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Frontotemporal Dementia Market Snippet by Drug Class
    • 2.1.2. Frontotemporal Dementia Market Snippet by Disease Indication
    • 2.1.3. Frontotemporal Dementia Market Snippet by Distribution Channel
    • 2.1.4. Frontotemporal Dementia Market Snippet by Country
    • 2.1.5. Frontotemporal Dementia Market Snippet by Region
  • 2.2. Competitive Insights

3. Frontotemporal Dementia Key Market Trends

  • 3.1. Frontotemporal Dementia Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Frontotemporal Dementia Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Frontotemporal Dementia Market Opportunities
  • 3.4. Frontotemporal Dementia Market Future Trends

4. Frontotemporal Dementia Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Frontotemporal Dementia Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Frontotemporal Dementia Market Landscape

  • 6.1. Frontotemporal Dementia Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Frontotemporal Dementia Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 7.1.2. Cognitive Enhancers
    • 7.1.3. Antidepressants
    • 7.1.4. Antipsychotics
    • 7.1.5. CNS Stimulants
    • 7.1.6. Other Drug Classes

8. Frontotemporal Dementia Market - By Disease Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
    • 8.1.2. Frontotemporal Dementia
    • 8.1.3. Movement Disorders
    • 8.1.4. Primary Progressive Aphasia

9. Frontotemporal Dementia Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Retail Pharmacies

10. Frontotemporal Dementia Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Frontotemporal Dementia Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Frontotemporal Dementia Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Frontotemporal Dementia Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Frontotemporal Dementia Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Frontotemporal Dementia Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Frontotemporal Dementia Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Transposon Therapeutics
    • 11.2.2. AstraZeneca plc
    • 11.2.3. Alector Inc.
    • 11.2.4. Pfizer Inc.
    • 11.2.5. Denali Therapeutics Inc.
    • 11.2.6. Johnson & Johnson Services Inc.
    • 11.2.7. Prevail Therapeutics
    • 11.2.8. Wave Life Sciences
    • 11.2.9. GlaxoSmithKline plc
    • 11.2.10. TauRx Pharmaceuticals Ltd.
    • 11.2.11. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us